• Caris Life Sciences to Present Key Research Findings at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting

    Research Demonstrates Clinical Utility of Caris Molecular Intelligence and Illustrates the Positive Impact Following its Proprietary Recommendations can have on the Treatment and Survival of Cancer Patients

     IRVING, Tex., May 31, 2016 Caris Life Sciences®, a leading biotechnology company focused on fulfilling the promise of precision medicine, announced today the acceptance of 19 clinical studies by the American Society of Clinical Oncology (ASCO) for presentation at its annual meeting to be held June 3 through June 7 in Chicago, Ill.  The studies were conducted in collaboration with industry-leading academic and clinical institutions across the United States and Europe using Caris Molecular Intelligence® (CMI), the company’s patented and proprietary offering that helps guide therapy decisions in the treatment of cancer. Evidence has shown that when physicians follow the recommendations of CMI, it can result in an increase in overall survival of 9 months to over one year, and 1.2 fewer lines of therapy, in patients with certain cancer types.

    One of the studies, performed in collaboration with leading researchers from the Lombardi Comprehensive Cancer Center at Georgetown University, Levine Cancer Institute, Karmanos Cancer Institute, Fox Chase Cancer Center and Arizona State University, investigates the novel panomic validation of Time to Next Treatment (TNT) as an effective surrogate outcome measure in over 4700 patients. This poster discussion will be presented by John Marshall, MD, of the Lombardi Comprehensive Cancer Center at Georgetown University on June 6, 2016. In addition, researchers from Caris and the Fox Chase Cancer Center will host an oral abstract session on Tuesday, June 7, regarding a joint study that utilized fusion analysis of solid tumors to reveal novel rearrangements in breast cancer.  Details for each of these presentations are outlined below.

    Each of the other studies being presented was conducted in collaboration with leading academic and clinical institutions, including the University of Bonn (Bonn, Germany), Lombardi Comprehensive Cancer Center at Georgetown University, The Levine Cancer Institute, Karmanos Cancer Institute, Fox Chase Cancer Center, Virginia Cancer Specialists and Arizona State University. The use of Caris Molecular Intelligence enabled investigators to identify the biological heterogeneity of certain types of cancers and to identify therapeutic options, including therapies with potential benefit to consider and, just as important, therapies to avoid due to potential lack of benefit.

    Following is a schedule of Caris Life Sciences’ ASCO presentations:

    • Monday June 6, 4:45– 6:00 p.m. CT, S406

    Poster Discussion Session: Tumor Biology “Novel panomic validation of time to next treatment (TNT) as an effective surrogate outcome measure in 4,729 patients” presented by John Marshall, MD, Lombardi Comprehensive Cancer Center, Georgetown University, Abstract 11521, Poster 218.

    • Tuesday June 7, 9:12– 9:24 a.m. CT, S100a

    Oral Abstract Session: Tumor Biology “Fusion analysis of solid tumors to reveal novel rearrangements in breast carcinomas” presented by Igor A. Astsaturov, MD, PhD, Fox Chase Cancer Center, Abstract 11504.

    Following is a schedule of Caris Life Sciences’ poster sessions:

    • Saturday June 4, 8:00– 11:30 a.m. CT, Hall A

    Poster session: Gastrointestinal (Colorectal) Cancer “Comparative molecular analyses of BRAF-V600E mutant tumors: Colorectal cancers (CRC) vs. melanomas” presented by Shelly Ann Christiansen, MD, Georgetown University Hospital, Abstract 3598, Poster 295.

    • Saturday June 4, 8:00– 11:30 a.m. CT, Hall A

    Poster session: Gastrointestinal (Colorectal) Cancer “Comparative molecular analyses of colon versus rectal tumors” presented by John Marshall, MD, Lombardi Comprehensive Cancer Center, Georgetown University, Abstract 3552, Poster 249.

    • Saturday, June 4, 8:00– 11:30 a.m. CT, Hall A

    Poster session: Gastrointestinal (Colorectal) Cancer “Ras family mutation patterns in a large cohort of CRCs” presented by Joanne Xiu, PhD, Caris Life Sciences, Abstract 3599, Poster 296.

    • Saturday, June 4, 8:00– 11:30 a.m. CT, Hall A

    Poster session: Gastrointestinal (Colorectal) Cancer “Comparative molecular analyses of esophageal cancer: Adenocarcinoma vs. squamous cell carcinomas and impact on outcome” presented by Mohamed E. Salem, MD, Lombardi Comprehensive Cancer Center, Georgetown University, Abstract 4035, Poster 27

    • Saturday, June 4, 8:00– 11:30 a.m. CT, Hall A

    Poster session: Gastrointestinal (Colorectal) Cancer “Comparative molecular analyses of pancreatic cancer (PC): KRAS wild type vs. KRAS mutant tumors and primary tumors vs. distant metastases” presented by Mohamed E. Salem, MD, Lombardi Comprehensive Cancer Center, Georgetown University, Abstract 4121, Poster 113.

    • Saturday, June 4, 1:00– 4:30 p.m. CT, Hall A

    Poster session: Central Nervous System Tumors “Comparison of molecular alteration in glioblastoma tumors from old and young patients” presented by Joanne Xiu, PhD, Caris Life Sciences, Abstract 2056, Poster 243.

    • Saturday, June 4, 1:00– 4:30 p.m. CT, Hall A

    Poster session: Health Services Research and Quality of Care “Differences in the molecular landscape of cancer between African American (AA) and Caucasian (CC) cancer patients” presented by Elisabeth I. Heath, MD, Karmanos Cancer Institute, Wayne University, Abstract 6558, Poster 45.

    • Saturday, June 4, 1:00– 4:30 p.m. CT, Hall A

    Poster session: Genitourinary (Prostate) Cancer “Use of panomic assessment to reveal DNA repair alterations and to predict potential therapeutic response to taxane-platinum combination therapy in prostate cancer” presented by Nancy Ann Dawson, MD, Lombardi Comprehensive Cancer Center, Abstract 5040, Poster 297.

    • Saturday, June 4, 1:00– 4:30 p.m. CT, Hall A

    Poster session: Melanoma/Skin Cancers “Disparity in PD-L1 expression between metastatic uveal and cutaneous melanoma” presented by Asad Javed, MD, Department of Medical Oncology, Kimmel Cancer Center, Thomas Jefferson University, Abstract 9541, Poster 146.

    • Sunday June 5, 8:00– 11:30 a.m. CT, Hall A

    Poster session: Breast Cancer – Triple-Negative/Cytotoxics/Local Therapy “Predictive value of topoisomerase 1 immunohistochemistry (TOP1 IHC) in patients with metastatic breast cancer receiving irinotecan-based therapy” presented by Nicholas J. Robert, MD, The US Oncology Network, Abstract 1037, Poster 142.

    • Monday, June 6, 1:00– 4:30 p.m. CT, Hall A

    Poster session: Tumor Biology “Distribution of PD-L1 expression in diverse cancer types: Experience with over 10,000 cases” presented by Zoran Gatalica, MD, DSc, Caris Life Sciences, Abstract 11548, Poster 245.

    • Monday, June 6, 1:00– 4:30 p.m. CT, Hall A

    Poster session: Tumor Biology “Tumor profiling of liver metastases (LM) from CRC, NSCLC, pancreatic (PC), breast (BC) and gastroesophageal (GE) tumors to reveal differences versus primary tumors including in cMET, MYC, CDK4, Her2, b-catenin and PD1”presented by Wafik S. El-Deiry, MD, PhD, Fox Chase Cancer Center, Abstract 11604, Poster 301.

    About Caris Life Sciences®

    Founded by David D. Halbert in 2008, Caris Life Sciences® is a leading biotechnology company focused on fulfilling the promise of precision medicine through quality and innovation. With more than 90,000 patients profiled, Caris Molecular Intelligence® (CMI) the company’s patented and proprietary product offering, provides oncologists with the most clinically actionable treatment options available to personalize cancer care today. Caris Molecular Intelligence uses a variety of advanced profiling technologies to assess relevant biological changes in each patient’s tumor.  CMI then connects the biomarker data generated from the tumor with biomarker-drug associations supported by the evidence and in relevant clinical literature through the Company’s proprietary bioinformatics rules engine. Since 2009, Caris Life Sciences has tracked clinical and outcome data for certain patients utilizing CMI, and has observed that patients treated with drugs consistent with CMI’s recommendations based upon the patient’s tumor profile show a significant increase in overall survival. The company is also developing its ADAPT Biotargeting System, a revolutionary and unbiased profiling platform with applications across therapy development, drug delivery, advanced diagnostics and disease monitoring. Currently being developed for cancer and other complex diseases, the ADAPT Biotargeting System is able to simultaneously measure millions of molecular interactions within complex biological systems in their natural state(s). Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Australia and other international markets. To learn more, please visit www.CarisLifeSciences.com.

     

    Leave a reply →

Photostream